Randomized trials of anti-EGFR antibodies in advanced colorectal cancer: second line and beyond [a]

Study	Total number of patients	Treatment regimen	Study population as a whole			KRAS wild-type population		
			RR	PFS	OS, mo	RR	PFS	OS, mo
Cetuximab								
Cunningham et al[15]	329	Cetuximab	11%	1.5 mo	6.9	–	–	–
		Irinotecan-cetuximab	23%	4.1 mo	8.6	–	–	–
Jonker et al[16]; Karapetis et al[17]	572	Best supportive care	0%	–	4.6	0%	1.9 mo	4.8
		Cetuximab	8%	–	6.1	13%	3.7 mo	9.5
Sobrero et al[18]	1,298	Irinotecan	4%	2.6 mo	10.0	–	–	–
		Irinotecan-cetuximab	16%	4.0 mo	10.7	–	–	–
Panitumumab								
Van Cutsem et al[31]; Amado et al[32]	463	Best supportive care	0%	7.3 wk	–	0%	7.3 wk	7.6
		Panitumumab	10%	8.0 wk	–	17%	12.3 wk	8.1
Peeters et al[33]	1,186	FOLFIRI	–	–	–	10%	3.9 mo	12.5
		FOLFIRI-panitumumab	–	–	–	35%	5.9 mo	14.5

EGFR = epidermal growth factor receptor; RR = response rate; PFS = progression-free survival; OS = overall survival; FOLFIRI = folinic acid, 5-fluorouracil, irinotecan
[a] Excluding bevacizumab-containing trials